Home Genetic Testing Basics Genetic Panel Test: Multiple Genes, Disease Risk, and Results

Genetic Testing Basics

Genetic Panel Test: Multiple Genes, Disease Risk, and Results

July 31, 2026 Modified date: July 31, 2026

Learn how genetic panel tests analyze multiple genes, when panels are useful, how positive, negative, and uncertain results are interpreted, and what limits to consider.

A genetic panel test examines several genes at the same time to look for variants linked to a particular disease, symptom pattern, or inherited risk. Panels are useful when many genes can cause similar problems, such as epilepsy, cardiomyopathy, hearing loss, hereditary cancer, or immune deficiency. Testing multiple relevant genes can shorten the search for a diagnosis and may cost less than ordering genes one by one.

A broader test is not automatically a better test. The value of a panel depends on whether its genes have a well-established connection to the clinical question, whether the laboratory can detect the expected variant types, and whether the results can guide care. Large panels also create more opportunities to find variants of uncertain significance or risk findings unrelated to the original concern. Before testing, patients should understand the panel’s scope, possible result categories, family implications, privacy considerations, and the chance that the test will not provide a clear answer.

A genetic panel tests multiple related genes in one analysis and is most useful when several genes can cause the same or overlapping condition.
A positive result usually identifies a pathogenic or likely pathogenic variant, but the finding must fit the person’s symptoms and inheritance pattern.
A negative panel does not exclude every genetic cause because untested genes, difficult variant types, and unknown disease genes may remain.
The chance of a variant of uncertain significance generally rises as more genes are included.
Panel size should be based on clinical relevance, not simply the largest number of genes available.
Testing an affected relative first often makes a family-risk panel more informative.

What a Genetic Panel Tests
When a Panel Is a Good Choice
Focused Panels, Broad Panels, and Test Design
How the Sample Is Analyzed
Positive, Negative, and Uncertain Results
Disease Risk, Inheritance, and Family Testing
Benefits, Risks, and Limitations
Choosing a Panel and Using the Report

What a Genetic Panel Tests

A genetic panel is a group of genes analyzed together because they are associated with a shared clinical problem. The panel may target a single condition with several possible genetic causes, a group of disorders that look alike, or an inherited risk category such as hereditary cancer or heart disease.

For example, hypertrophic cardiomyopathy can result from variants in several sarcomere genes. Epilepsy can arise from hundreds of genes affecting ion channels, synapses, metabolism, or brain development. Hereditary breast and ovarian cancer testing may include high-risk genes such as BRCA1 and BRCA2 along with other genes that carry moderate or syndrome-specific risks. A panel can evaluate these possibilities in parallel.

Most clinical panels use next-generation sequencing, which reads many DNA segments at once. The laboratory compares the sequence with a reference and identifies differences called variants. It then filters and classifies variants according to the clinical reason for testing, scientific evidence, population frequency, predicted effect, family data, and other information.

A panel name does not guarantee identical content across laboratories. Two “cardiomyopathy panels” may contain different genes, cover different regions, and use different methods for deletions, duplications, repeat expansions, or mitochondrial variants. The report or test description should identify:

Every gene included.
Which exons or other regions were analyzed.
Whether deletion and duplication analysis was performed.
Whether mitochondrial DNA, repeat expansions, or structural variants were included.
Coverage thresholds and regions with reduced sensitivity.
The laboratory’s policy for uncertain, secondary, and carrier findings.

A multigene panel test is narrower than whole-exome or whole-genome sequencing because the analysis concentrates on a selected gene list. However, the laboratory may technically sequence a much larger set and restrict the initial interpretation to the ordered virtual panel. This can allow later reanalysis if the person develops new features or if new genes are added to the disease category.

When a Panel Is a Good Choice

A panel is well suited to genetically heterogeneous conditions, meaning disorders that can be caused by variants in many different genes. It is also helpful when several syndromes share the same signs and cannot be separated confidently through examination alone.

Common reasons to order a panel include:

Symptoms strongly suggest an inherited disorder, but no single gene clearly stands out.
More than one gene is routinely associated with the diagnosis.
The person has features that cross traditional syndrome boundaries.
Earlier single-gene testing was negative or incomplete.
A result could change treatment, surveillance, or reproductive planning.
The family history suggests inherited risk but does not identify one specific syndrome.

A focused panel may be more efficient than sequential testing. Imagine a child with progressive hearing loss. Variants in many nuclear and mitochondrial genes can produce similar hearing patterns, and some forms include later vision, kidney, thyroid, or cardiac problems. A carefully designed hearing-loss panel may identify the cause before those additional features become obvious.

Panel testing can also be used for predictive or risk assessment in an unaffected person. In that setting, the panel should match a documented family pattern or guideline-based indication. Testing an affected relative first is usually more informative because a negative result in an unaffected person may not reveal whether the family’s unexplained condition has a detectable genetic cause.

A panel may be less suitable when one specific mechanism requires a specialized assay. Huntington disease, fragile X syndrome, myotonic dystrophy, and several ataxias involve repeat expansions that standard sequence panels may not reliably detect. Some imprinting disorders require methylation testing. Balanced chromosome rearrangements may require a karyotype. The clinical team should choose the method before deciding how many genes to include.

A broader whole-exome sequencing test may be preferable for a person with multiple unexplained organ-system findings, severe developmental differences, or a long negative testing history. The choice between a panel and exome or genome testing depends on diagnostic yield, cost, turnaround time, consent needs, and whether the likely variant types are detectable.

Focused Panels, Broad Panels, and Test Design

Panel quality depends more on gene selection and assay design than on the total gene count. A 20-gene panel containing well-validated genes may be more clinically useful than a 200-gene panel filled with weak or disputed associations.

Focused panels

Focused panels include genes with a strong connection to a defined condition. They tend to produce fewer unrelated findings and fewer uncertain variants. They may also simplify insurance review and result interpretation. A focused panel works best when the clinical diagnosis is reasonably specific, such as long QT syndrome, Marfan syndrome, familial hypercholesterolemia, or Lynch syndrome.

Broad phenotype panels

Broad panels cover a larger group, such as inherited retinal disease, neurodevelopmental disorders, connective-tissue disease, or primary immunodeficiency. They are useful when symptoms overlap several conditions or evolve over time. Their main tradeoff is a greater chance of identifying uncertain findings in genes that only loosely match the patient.

Pan-condition and expanded panels

Some laboratories offer very large panels spanning hundreds of genes or multiple syndromes. These may help when referral information is limited or the phenotype is complex, but they can blur the line between diagnostic testing and broad screening. They may identify disease risks that the patient did not expect to learn about.

Panel type	Main advantage	Main tradeoff
Single-condition focused panel	Clear clinical relevance and simpler interpretation	May miss an unexpected diagnosis with similar features
Phenotype-based broad panel	Covers overlapping disorders efficiently	More uncertain findings and variable gene evidence
Very large multisystem panel	Wide search without moving directly to exome or genome testing	Higher burden of incidental, carrier, and uncertain results
Virtual panel from exome or genome data	Can be updated or expanded later without resequencing	Data generation and consent may be broader than the first analysis

Gene validity should be considered separately from variant classification. A variant can be damaging to a gene, yet the gene itself may not have a proven relationship with the person’s condition. Reliable laboratories distinguish established disease genes from genes with limited or emerging evidence and avoid presenting speculative associations as confirmed diagnoses.

How the Sample Is Analyzed

Most panel tests use blood or saliva. Blood often provides consistent DNA quantity and may be preferred when mosaicism, blood disorders, bone-marrow transplant history, or sample quality could affect interpretation. Saliva or cheek swabs are convenient but may contain mixed cell types and can occasionally require recollection.

The testing process usually follows these stages:

Clinical ordering and consent. The clinician selects the panel and documents the reason for testing, personal history, family history, and consent choices.
DNA extraction and sequencing. The laboratory isolates DNA and sequences the selected genes or a larger dataset used for virtual analysis.
Quality review. Bioinformatics systems align the DNA reads, check coverage, and flag possible variants.
Variant confirmation and classification. The laboratory evaluates relevant variants and may confirm certain findings with a second method.
Clinical interpretation. The findings are compared with the person’s features and known inheritance patterns.
Reporting. The report lists clinically relevant findings, limitations, recommendations, and sometimes secondary or carrier results.

Turnaround time often ranges from two to eight weeks, though urgent panels may be completed faster and highly specialized tests may take longer. No fasting or medication changes are usually needed. A transfusion, active blood cancer, stem-cell transplant, or transplant from a donor can complicate blood-based germline testing, so the laboratory needs accurate clinical information.

Panel analysis is not simply a computer scan. Human review remains important because phenotype detail can determine which variants are reported and how strongly they fit. A laboratory evaluating a seizure panel may interpret the same variant differently when it knows whether seizures began in infancy, whether development was normal beforehand, and whether brain imaging shows a specific pattern.

Testing parents with a child, called trio testing, can improve interpretation. It can reveal whether a variant is new in the child, inherited from an unaffected parent, or paired with another variant on the opposite gene copy. Trio data may reduce uncertainty, although it does not guarantee a diagnosis.

Positive, Negative, and Uncertain Results

Panel results are commonly grouped as positive, negative, or uncertain, but the full interpretation is more informative than the label.

Positive result

A positive result identifies a pathogenic or likely pathogenic variant that explains the condition or establishes an inherited risk. The report should state why the variant is clinically relevant, whether one or two altered gene copies are required, and how well the finding matches the person’s features.

Some panels find more than one important result. A person may receive a diagnosis in one gene and an unrelated actionable risk in another. Another person may carry pathogenic variants for two recessive conditions without being affected. Each finding needs a separate interpretation.

Negative result

A negative result means no reportable disease-causing variant was found in the genes and regions analyzed. It can lower the probability of the tested disorders but does not eliminate genetic disease. The cause may involve a gene not on the panel, a variant type the assay misses, mosaicism, a regulatory region, or a gene not yet linked to the condition.

The report’s gene list and limitations are essential. A “negative 50-gene panel” and a “negative 500-gene panel” do not have the same scope, but neither necessarily detects repeat expansions, balanced rearrangements, methylation changes, or all copy-number variants.

Variant of uncertain significance

A VUS is a DNA change without enough evidence to determine whether it causes disease. Large panels increase the number of variants examined and therefore the chance of finding at least one VUS. Research across clinical laboratories has shown that uncertain-result rates rise with panel size, though the exact rate varies by specialty, ancestry, laboratory policy, and whether relatives are tested.

A VUS should not be treated as a confirmed diagnosis. It generally should not prompt preventive surgery, permanent treatment changes, or predictive testing of healthy relatives as though it were pathogenic. Clinical care should remain based on symptoms and family history unless new evidence changes the classification. More detail is available in the guide to a variant of uncertain significance result.

Result	Useful follow-up question
Pathogenic or likely pathogenic	Does the variant fully explain the findings, and what care changes are recommended?
No clinically significant variant	What causes and variant types remain outside the test?
VUS	Would testing selected relatives or later reanalysis help?
Carrier finding	Does it affect reproductive risk or indicate testing for a partner?
Secondary finding	Is the risk actionable, and what confirmation or surveillance is needed?

Disease Risk, Inheritance, and Family Testing

A panel result may diagnose a current disorder, predict future risk, identify carrier status, or clarify risk for relatives. These uses should not be mixed together because they carry different levels of certainty and different medical consequences.

For an autosomal dominant condition, one pathogenic variant may be enough to increase risk, and each child of a carrier often has a 50% chance of inheriting it. Risk may still be incomplete because penetrance and severity differ. For an autosomal recessive condition, two pathogenic variants in the same gene are generally needed. The report should establish whether they are in trans, meaning on opposite copies of the gene. X-linked and mitochondrial findings require their own inheritance analysis.

The best person to test first is usually the relative most clearly affected, especially the person with the earliest onset, most distinctive features, or most complete records. If a pathogenic variant is found, relatives can receive targeted testing for that exact change rather than repeating the whole panel.

A negative targeted result in a relative can be very reassuring when the family variant is known. A negative broad panel in an unaffected person is harder to interpret because the family may have a genetic cause that the test did not identify.

Family testing can also help classify a VUS, but it should be planned with the laboratory or genetics team. Testing many unaffected relatives without a clear segregation question may add little. The most informative relatives are chosen based on who has the condition, who does not, age, degree of relationship, and the expected inheritance pattern.

Panel findings may affect reproductive options. Carrier couples may consider prenatal diagnosis, preimplantation genetic testing, donor gametes, adoption, or natural conception with postnatal testing. These are personal choices, and the purpose of counseling is to explain options rather than direct one decision.

Benefits, Risks, and Limitations

The main benefit of panel testing is efficiency. One test can evaluate many plausible causes, reduce repeated sample collection, and shorten the time to a molecular diagnosis. A result may guide treatment, stop unnecessary investigations, identify preventable complications, and alert relatives.

Panel testing also has drawbacks:

Uncertain results: More genes create more opportunities for VUS findings.
Unexpected risks: A panel may identify a condition unrelated to the original concern.
Variable evidence: Not every included gene has the same level of disease validity.
Incomplete detection: Sequencing may miss repeats, structural changes, mosaicism, methylation abnormalities, or hard-to-read regions.
Psychological impact: Results can cause anxiety, guilt, or conflict within families.
Insurance and privacy concerns: Legal protections vary by country and may not cover every form of insurance or employment.
Changing interpretation: Gene-disease relationships and variant classifications can be revised.

A larger panel does not necessarily increase the diagnostic yield in proportion to its size. Extra genes may add mostly uncertain findings, especially when they have little connection to the phenotype. Good test selection balances the chance of a useful answer against the burden of ambiguity.

Ancestry also affects interpretation. People from populations underrepresented in genetic databases are more likely to receive uncertain results because fewer comparison data are available. This is a limitation of the evidence base, not an indication that their DNA is unusually abnormal.

Cost and coverage vary. Insurers may require clinical criteria, prior authorization, genetic counseling, or testing of an affected relative. Patients should ask about laboratory billing policies, self-pay prices, confirmation costs, and whether family testing is included.

Choosing a Panel and Using the Report

A well-chosen panel begins with a clear clinical question. Before ordering, the clinician and patient should agree on what the test is meant to resolve and how different result types could change care.

Useful questions before testing include:

Which condition or risk is being evaluated?
Why is a panel preferable to a single-gene test, chromosome test, exome, or genome?
How were the genes selected, and are all of them clinically validated?
Does the assay include deletion and duplication analysis?
Are repeat expansions, mitochondrial variants, or mosaicism relevant?
Will the laboratory report VUS, carrier findings, and secondary findings?
Can the patient decline categories of unrelated results?
What happens if the result is negative?
Is testing an affected relative first possible?
Who will explain the results and arrange follow-up?

After testing, obtain the full report. Check the exact panel version because laboratories update gene lists over time. The report should include the genes tested, method, findings, classification, inheritance, limitations, and recommendations. Keep it with other medical records and share it with specialists who manage the related condition.

A positive result should lead to condition-specific care, not a generic response. A negative result should prompt a review of residual risk and whether another method is appropriate. A VUS should be documented and periodically revisited without being allowed to drive unsupported interventions.

Reanalysis may be helpful when new symptoms appear, a relative receives a diagnosis, or scientific evidence changes. Some laboratories automatically review reported variants; others require a new request. Ask who is responsible for recontact and how current contact information will be maintained.

Genetic counseling can be useful before and after panel testing, particularly for broad panels, adult-onset risks, reproductive questions, hereditary cancer, cardiac conditions, or uncertain findings. The strongest result is not simply the one with the most genes. It is the one that answers a defined clinical question with evidence that can be used safely.

References

Disclaimer

A genetic panel should be selected and interpreted using the person’s medical and family history. Panel results do not replace clinical evaluation, and a negative or uncertain result may still require follow-up. Discuss testing choices, disease-risk findings, and family implications with the ordering clinician or a qualified genetics professional.